AVArnauld C. Verschuur

Arnauld C. Verschuur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arnauld C. Verschuur has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment of Pulmonary Metastases in Children With Stage IV Nephroblastoma With Risk-Based Use of Pulmonary Radiotherapy

    by Arnauld Verschuur, Harm Van Tinteren, Norbert Graf, Christophe Bergeron, Bengt Sandstedt, Jan de Kraker

    Purpose: The purpose of this study was to determine the outcome of children with nephroblastoma and pulmonary metastases (PM) treated according to International Society of Pediatric Oncology (SIOP) 93-01 recommendations using pulmonary radiotherapy (RT) in selected patients. Patients and Methods: Patients (6 months to 18 years) were treated with preoperative chemotherapy consisting of 6 weeks of vincristine, dactinomycin, and epirubicin or doxorubicin. If pulmonary complete remission (CR) was not obtained, metastasectomy was considered. Patients in CR received three-drug postoperative chemotherapy, whereas patients not in CR were switched to a high-risk (HR) regimen with an assessment at week 11. If CR was not obtained, pulmonary RT was mandatory. Results: Two hundred thirty-four of 1,770 patients had PM. Patients with PM were older (P < .001) and had larger tumor volumes compared with nonmetastatic patients (P < .001). Eighty-four percent of patients were in CR postoperatively, with 17% requiring metastasectomy. Thirty-five patients (16%) had multiple inoperable PM and required the HR protocol. Only 14% of patients received pulmonary RT during first-line treatment. For patients with PM, 5-year event-free survival rate was 73% (95% CI, 68% to 79%), and 5-year overall survival (OS) rate was 82% (95% CI, 77% to 88%). Five-year OS was similar for patients with local stage I and II disease (92% and 90%, respectively) but lower for patients with local stage III disease (68%; P < .001). Patients in CR after chemotherapy only and patients in CR after chemotherapy and metastasectomy had a better outcome than patients with multiple unresectable PM (5-year OS, 88%, 92%, and 48%, respectively; P < .001). Conclusion: Following the SIOP protocol, pulmonary RT can be omitted for a majority of patients with PM and results in a relatively good outcome.


  • Les tumeurs stromales gastro-intestinales (GIST) en pédiatrie : une revue de la littérature de cette maladie orpheline

    by Arnauld Verschuur, Nicolas André, Jean-Yves Blay

    Recommendations for the management of gastrointestinal stromal tumours (GIST) in children and adolescents do presently not exist. Thus, a summary of the current literature was conducted serving as a basis for the development of optimal management strategies for childhood GIST. Pediatric cases of GIST may occur sporadically, or within a predisposition syndrome such as Carney triad or Carney-Stratakis syndrome. Moreover, cases with familial GIST have been reported. The frequency of mutations of the oncogenes KIT and PDGFRα in sporadic GIST is substantially lower as compared with adults with GIST. An international prospective registration based on national registries has recently been started in order to acquire more clinical and molecular data and to develop appropriate management strategies for children and adolescents with GIST.


  • Stromal and epithelial predominant Wilms tumours have an excellent outcome: The SIOP 93 01 experience

    by Arnauld C. Verschuur, Gordan M. Vujanic, Harm Van Tinteren, Kathy Pritchard Jones, Jan de Kraker, Bengt Sandstedt

    Background: Wilms tumour (WT) has various subtypes that are correlated with prognosis and require distinct therapy. Stromal predominant (SpWT) and epithelial WT (EpWT) have previously been associated with a good outcome. The current analysis describes the outcome and (tumour) characteristics of all patients with SpWT, EpWT, including highly differentiated epithelial type (HDET), treated according to the International Society of Pediatric Oncology (SIOP) 93‐01 study.Procedure: All children older than 6 months and below 18 years of age with localized or metastatic WT and intermediate risk (IR) histology or HDET treated with pre‐operative chemotherapy were included in the present analysis.Results: A total of 1,389 eligible patients had IR or HDET histology: 1% HDET, 4% EpWT, 10% SpWT, and 85% other IR. For EpWT/HDET, 93% had stage I/IIN−, 5‐year EFS was 90.2% and overall survival of (OS) 98.4%, as compared to 84.0% and 92.5% in other IR histology (NS). Stage I EpWT/HDET had a significant better outcome than stage I of other IR. In SpWT 82% of cases had stage I/IIN−; 5‐year EFS was 94.3% and OS 99.2%, significantly better compared to other IR histology. All patients with stage I are alive (2/149 relapses); 3/52 stage IIN−, 2/21 stage IIN+/III, and 6/12 stage IV patients relapsed (1 deceased per stage group).Conclusions: The good outcome for EpWT and SpWT generally is very good which may be related to low age and low stage in most cases. A reduction of treatment intensity and/or duration may be justified especially for low stage SpWT that has an EFS close to 100%. Pediatr Blood Cancer 2010;55:233–238. © 2010 Wiley–Liss, Inc.


  • Veno‐occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico‐pathological analysis

    by Charissa T. Jagt, Michelle Zuckermann, Fibo Ten Kate, Jan A.J.M. Taminiau, Marcel G.W. Dijkgraaf, Hugo Heij, Jan De Kraker, Arnauld C. Verschuur

    Background: Vincristine (VCR) and actinomycin D (ACD) form the backbone of chemotherapeutic regimens of Wilms tumor treatment. Veno‐occlusive disease (VOD) is a potentially life‐threatening complication of ACD.Objectives: To investigate the incidence of VOD after preoperative chemotherapy and assess the effect of dose and frequency of administrating ACD on the occurrence of VOD.Methods: A single‐center retrospective study of patients where liver biopsies were performed after 4 or 8 weeks of preoperative chemotherapy. Patients had localized or metastatic Wilms tumor and were treated according to SIOP 9, 93‐1, or 2001 protocol. A correlation was analyzed between histologically confirmed VOD, laboratory parameters, and mode and frequency of ACD administration. Long‐term hepatic toxicity was assessed 5 years after the end of therapy.Results: Ninety‐one patients were included in this analysis. Forty‐one patients (45.1%) had histological evidence of VOD. The incidence of histologically proven VOD was significantly correlated with single administration of 45 µg/kg ACD (SIOP 2001 protocol) as compared to repeated dosing of l5 µg/kg (P = 0.003). Fifty‐two percent of all patients had mild‐to‐severe abnormal liver enzymes 5 years after accomplishing therapy.Conclusion: Despite short‐course preoperative chemotherapy regimen, patients are at risk of developing histological VOD. This risk is higher when ACD is administered in a 1‐day 45 µg/kg regimen as compared to 3 days l5 µg/kg. Pediatr Blood Cancer 2009; 53:1211–1215.